Hyperlipoproteinaemia is one of the main risk factors of ischaemic heart disease. The centre of gravity of its pharmacotherapy with hypolipidaemic agents is secondary prevention of ischaemic heart disease. In patients in primary prevention of ischaemic heart disease pharmacotherapy is indicated only in case of high risk, if non-pharmacological treatment does not lead to achieve- ment of target values of blood lipids. Available hypolipidaemic drugs on our market include statins, fibrates and resins. A suitable preparation should be selected with regard to the type of hyperlipidaemia. A constant part of treatment with hypolipidaemic drugs must be also non-phar- macological treatment which in the majority should precede pharmacotherapy.

        Key words: Hypolipidaemic drugs - Ischaemic heart disease - Hyperlipoproteinaemia - Pharma-